Login to Your Account

Clinic Roundup

Thursday, August 29, 2013
Orexo AB, of Uppsala, Sweden, said it completed a dose-finding study of OX51, a sublingual formulation comprising alfentanil, in patients undergoing prostate biopsy, with the trial meeting its primary endpoint of analgesic efficacy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription